Multiple endocrine neoplasia type 2 other imaging findings: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
(Mahshid)
 
(12 intermediate revisions by 3 users not shown)
Line 4: Line 4:


==Overview==
==Overview==
Other imaging studies for multiple endocrine neoplasia type 2 include fluoro-di-glucose-[[PET]], [18F]-fluorodopamine ([18F]DA) [[PET]], and [[Tc-99m sestamibi scintigraphy|99mTc-sestamibi scintigraphy]].


==Other Imaging Studies==
==Other Imaging Studies==
===Medullary Thyroid Carcinoma===
===Medullary Thyroid Carcinoma===
* Radioactive iodine: lesions do not concentrate radioactive iodine since the tumour does not arise from thyroid follicular cells.
* Radioactive [[iodine]]: Lesions do not concentrate radioactive [[iodine]] since the [[tumor]] does not arise from [[thyroid]] follicular cells.
* FDG-PET: avid uptake<ref name=Radiopaedia 2015 Medullary throid carcinoma>{{cite web | title = Radiopedia 2015 Medullary throid carcinoma  [Dr Matt A. Morgan and Dr Yuranga Weerakkody]| url = http://radiopaedia.org/articles/medullary-thyroid-cancer }}</ref>
* FDG-[[PET]]: Avid uptake is seen.<ref name="Radiopaedia">{{cite web | title = Radiopedia 2015 Medullary throid carcinoma  [Dr Matt A. Morgan and Dr Yuranga Weerakkody]| url = http://radiopaedia.org/articles/medullary-thyroid-cancer }}</ref>
* Tl-201: It has been shown to concentrate Thallium-201<ref name="pmid2866591">{{cite journal| author=Talpos GB, Jackson CE, Froelich JW, Kambouris AA, Block MA, Tashjian AH| title=Localization of residual medullary thyroid cancer by thallium/technetium scintigraphy. | journal=Surgery | year= 1985 | volume= 98 | issue= 6 | pages= 1189-96 | pmid=2866591 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2866591  }} </ref>
* Tl-201: It has been shown to concentrate Thallium-201.<ref name="pmid2866591">{{cite journal| author=Talpos GB, Jackson CE, Froelich JW, Kambouris AA, Block MA, Tashjian AH| title=Localization of residual medullary thyroid cancer by thallium/technetium scintigraphy. | journal=Surgery | year= 1985 | volume= 98 | issue= 6 | pages= 1189-96 | pmid=2866591 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2866591  }} </ref>
* I-123 MIBG: 30% of MTCs show uptake if the thyroid is blocked with Lugol solution prior to the scan
* I-123 MIBG (metaiodobenzylguanidine): 30% of [[medullary thyroid cancer]] show uptake if the [[thyroid]] is blocked with [[Lugol's solution]] prior to the scan.
 
===Pheochromocytoma===
===Pheochromocytoma===
* [18F]-fluorodopamine ([18F]DA) PET is the best imaging modality for pheochromocytoma
* [18F]-fluorodopamine ([18F]DA) [[PET]] is the best imaging modality for [[pheochromocytoma]].
====I-123 MIBG (metaiodobenzylguanidine)====
====I-123 MIBG (metaiodobenzylguanidine)====
* MIBG (123I- or 131I- metaiodobenzylguanidine) scintigraphy is another imaging modality for pheochromocytoma
* MIBG (123I- or 131I- metaiodobenzylguanidine) [[scintigraphy]] is another imaging modality for [[pheochromocytoma]].
 
====Octreotide (somatostatin) scans====
====Octreotide (somatostatin) scans====
* Over 70% of tumours express somatostatin receptors. Imaging is obtained 4 hours (+/- 24/48 hours) after an intravenous infusion. Unfortunately the kidney also has somatostatin receptors, as do areas of inflammation, mammary glands, liver, spleen, bowel, gallbladder, thyroid gland and salivary glands. As such interpretation can be difficult.<ref>{{cite book | last = Pacak | first = Karel | title = Pheochromocytoma diagnosis, localization, and treatment | publisher = Blackwell Pub | location = Malden, MA Oxford | year = 2007 | isbn = 1405149507 }}</ref>
* Over 70% of [[tumor]]s express [[somatostatin]] receptors. Imaging is obtained 4 hours (+/- 24/48 hours) after an [[intravenous infusion]]. Unfortunately the [[kidney]] also has [[somatostatin receptor]]s, as well as areas of [[inflammation]], [[mammary gland]]s, [[liver]], [[spleen]], [[bowel]], [[gallbladder]], [[thyroid gland]] and [[salivary gland]]s.<ref>{{cite book | last = Pacak | first = Karel | title = Pheochromocytoma diagnosis, localization, and treatment | publisher = Blackwell Pub | location = Malden, MA Oxford | year = 2007 | isbn = 1405149507 }}</ref>
* Octreotide is usually labeled with either 111In-DTPA (Octreoscan) or (less commonly)123I-Tyr3-DTPA.
* [[Octreotide]] is usually labeled with either 111In-DTPA (Octreoscan) or (less commonly)123I-Tyr3-DTPA.
 
====PET====
====PET====
* 18F Dopa PET is thought to be highly sensitive according to initial results<ref name="pmid11818620">{{cite journal| author=Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I et al.| title=Pheochromocytomas: detection with 18F DOPA whole body PET--initial results.. | journal=Radiology | year= 2002 | volume= 222 | issue= 2 | pages= 507-12 | pmid=11818620 | doi=10.1148/radiol.2222010622 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11818620  }} </ref>
* 18F Dopa [[PET]] is thought to be highly sensitive according to initial results.<ref name="pmid11818620">{{cite journal| author=Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I et al.| title=Pheochromocytomas: detection with 18F DOPA whole body PET--initial results.. | journal=Radiology | year= 2002 | volume= 222 | issue= 2 | pages= 507-12 | pmid=11818620 | doi=10.1148/radiol.2222010622 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11818620  }} </ref>
 
===Parathyroid Carcinoma===
===Parathyroid Carcinoma===
* 99mTc-sestamibi scintigraphy is a good imaging modality for hyperparathyroidism.
* [[Tc-99m sestamibi scintigraphy|99mTc-sestamibi scintigraphy]] is a good imaging modality for [[hyperparathyroidism]].
<gallery>
<gallery>
Image:Nuclear medicine.jpg|Case courtesy of Dr Hani Al Salam, <ref>"http://radiopaedia.org/">Radiopaedia.org</a>. From the case <a href="http://radiopaedia.org/cases/7932">rID: 7932</ref>
Image:Nuclear medicine.jpg|Image courtesy of Dr Hani Al Salami<ref name=radio01>Image courtesy of Dr Hani Al Salami. [http://www.radiopaedia.org Radiopaedia] (original file[http://radiopaedia.org/cases/7932‘’here’’]).[http://radiopaedia.org/licence Creative Commons BY-SA-NC]</ref>
Image:Nuclear medicine 02.jpg|Case courtesy of Dr Roberto Schubert, <ref>"http://radiopaedia.org/">Radiopaedia.org</a>. From the case <a href="http://radiopaedia.org/cases/16148">rID: 16148</ref>
[http://radiopaedia.org/licence Creative Commons BY-SA-NC]</ref>
Image:Nuclear medicine 02.jpg|Image courtesy of Dr Roberto Schubert<ref name=radio02>Image courtesy of Dr Roberto Schubert. [http://www.radiopaedia.org Radiopaedia] (original file[http://radiopaedia.org/cases/16148‘’here’’]).[http://radiopaedia.org/licence Creative Commons BY-SA-NC]</ref>
[http://radiopaedia.org/licence Creative Commons BY-SA-NC]</ref>
</gallery>
</gallery>


==Reference==
==References==
{{Reflist|2}}
{{reflist|2}}
[[Category:Endocrinology]]
[[Category:Oncology]]
[[Category:Diseases]]
​​[[Category:Medicine]]
[[Category:Endocrinology]]
[[Category:Up-To-Date]]​
[[Category:Radiology]]
 
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Endocrinology]]
[[Category:Surgery]]

Latest revision as of 02:47, 27 November 2017

Multiple endocrine neoplasia type 2 Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple endocrine neoplasia type 2 from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

Diagnostic Criteria

History & Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Multiple endocrine neoplasia type 2 other imaging findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 other imaging findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple endocrine neoplasia type 2 other imaging findings

CDC on Multiple endocrine neoplasia type 2 other imaging findings

Multiple endocrine neoplasia type 2 other imaging findings in the news

Blogs on Multiple endocrine neoplasia type 2 other imaging findings

Directions to Hospitals Treating Multiple endocrine neoplasia type 2

Risk calculators and risk factors for Multiple endocrine neoplasia type 2 other imaging findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [4]

Overview

Other imaging studies for multiple endocrine neoplasia type 2 include fluoro-di-glucose-PET, [18F]-fluorodopamine ([18F]DA) PET, and 99mTc-sestamibi scintigraphy.

Other Imaging Studies

Medullary Thyroid Carcinoma

Pheochromocytoma

I-123 MIBG (metaiodobenzylguanidine)

Octreotide (somatostatin) scans

PET

  • 18F Dopa PET is thought to be highly sensitive according to initial results.[4]

Parathyroid Carcinoma

  • Image courtesy of Dr Hani Al Salami[5]

    Image courtesy of Dr Hani Al Salami[5]

  • Image courtesy of Dr Roberto Schubert[6]

    Image courtesy of Dr Roberto Schubert[6]

References

  1. ↑ "Radiopedia 2015 Medullary throid carcinoma [Dr Matt A. Morgan and Dr Yuranga Weerakkody]".
  2. ↑ Talpos GB, Jackson CE, Froelich JW, Kambouris AA, Block MA, Tashjian AH (1985). "Localization of residual medullary thyroid cancer by thallium/technetium scintigraphy". Surgery. 98 (6): 1189–96. PMID 2866591.
  3. ↑ Pacak, Karel (2007). Pheochromocytoma diagnosis, localization, and treatment. Malden, MA Oxford: Blackwell Pub. ISBN 1405149507.
  4. ↑ Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I; et al. (2002). "Pheochromocytomas: detection with 18F DOPA whole body PET--initial results." Radiology. 222 (2): 507–12. doi:10.1148/radiol.2222010622. PMID 11818620.
  5. ↑ Image courtesy of Dr Hani Al Salami. Radiopaedia (original file[1]).Creative Commons BY-SA-NC
  6. ↑ Image courtesy of Dr Roberto Schubert. Radiopaedia (original file[2]).Creative Commons BY-SA-NC

​​​


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Multiple_endocrine_neoplasia_type_2_other_imaging_findings&oldid=1395290"